Balance Sheet

v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Current assets:    
Cash $ 245,373 $ 11,342
Accounts receivable, net 15,750 29,950
Prepaid expenses 18,341 13,210
Total current assets 279,464 54,502
Property and equipment, net 44,687 19,012
Other assets:    
Intellectual property, net 250,000 251,963
Deposits, long term 13,422 13,422
Total other assets 263,422 265,385
Total assets 587,573 338,899
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $56,318 and $62,241, respectively 1,394,315 1,199,536
Deferred revenue, short term 215,236 237,347
Settlement payable 15,000
Convertible notes payable, short term portion, net of debt discount 3,128,780
Notes payable, short term portion 250,000
Notes payable, related party 186,590 186,590
Total current liabilities 5,174,921 1,638,473
Long term debt:    
Deferred revenue, long term 245,935 401,346
Convertible notes payable, long term, net of debt discount 2,016,041
Warrant liability 175,975
Total long term debt 245,935 2,593,362
Total liabilities 5,420,856 4,231,835
Deficit:    
Preferred stock value 16,000 16,000
Common stock, $0.001 par value; 750,000,000 shares authorized, 253,286,285 and 244,086,285 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively 253,286 244,086
Common stock subscribed 200,000 100,000
Additional paid in capital 47,466,220 44,581,896
Accumulated deficit (52,771,032) (48,840,534)
Total stockholders' deficit attributable to BioCorRx, Inc. (4,829,910) (3,892,936)
Non-controlling interest (3,373)
Total deficit (4,833,283) (3,892,936)
Total liabilities and deficit 587,573 338,899
Series B Preferred Stock [Member]    
Deficit:    
Preferred stock value $ 5,616 $ 5,616

Source